Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
MediWound Ltd. MDWD
$10.42
+$0.04 (0.39%)
На 18:00, 12 мая 2023
+133.49%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
101376967.00000000
-
week52high
15.72
-
week52low
8.05
-
Revenue
26496000
-
P/E TTM
-4
-
Beta
1.05882300
-
EPS
-3.80000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wells Fargo | Overweight | Overweight | 18 мая 2022 г. |
| Aegis Capital | Buy | Buy | 21 мар 2022 г. |
| Aegis Capital | Buy | Buy | 17 авг 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 11 авг 2021 г. |
| Aegis Capital | Buy | 02 мар 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 16 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 04 янв 2023 г. |
| Cowen & Co. | Outperform | Outperform | 30 дек 2022 г. |
| Maxim Group | Buy | 22 дек 2022 г. | |
| Oppenheimer | Outperform | Outperform | 21 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
MediWound to Report First Quarter 2023 Financial Results
GlobeNewsWire
12 мая 2023 г. в 08:00
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
GlobeNewsWire
26 апр 2023 г. в 08:00
Data to be highlighted in oral and poster presentations YAVNE, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic solutions for tissue repair, today announced the Company will present updated clinical data from the three EscharEx® Phase 2 trials at the 2023 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society taking place in National Harbor, Maryland on April 26-30, 2023.
MediWound Ltd. (MDWD) Q4 2022 Earnings Call Transcript
Seeking Alpha
16 мар 2023 г. в 14:30
MediWound Ltd. (NASDAQ:MDWD ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors, IR Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Josh Jennings - TD Cowen Francois Brisebois - Oppenheimer Swayampakula Ramakanth - H.C.
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
16 мар 2023 г. в 09:56
MediWound (MDWD) delivered earnings and revenue surprises of -521.05% and 56.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
GlobeNewsWire
02 мар 2023 г. в 08:47
Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time